Fundraising Fox
Crystalystx
San Diego, US · Founded 2025 · 23 employees on LinkedIn · 6 known investors
Find your way into Crystalystx
Sign up to see every warm intro you have to Crystalystx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Crystalystx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid. Its lead investigational therapy is a selective URAT1 inhibitor designed to lower serum uric acid by targeting renal urate reabsorption pathways.
Founders & leadership
Investors · 6
How we know: the company's own site · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: Longwood Fund's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Crystalystx do?
- Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid. Its lead investigational therapy is a selective URAT1 inhibitor designed to lower serum uric acid by targeting renal urate reabsorption pathways.
- Who are Crystalystx's investors?
- Crystalystx's investors include Catalys Pacific, Novo Holdings, AN Venture Partners, Frazier Life Sciences, Lightstone Ventures, Longwood Fund.
- Where is Crystalystx headquartered?
- Crystalystx is headquartered in San Diego, US.